克莱尔更充分被招募,并在恢复试验的埃克塞特手臂治疗第一人之一。

第一埃克塞特患者启动世界上最大的covid-19治疗试验

患者与covid-19埃克塞特正在招募最大的临床试验在世界范围内调查现有药物,这可能是对疾病有效。

试,被称为 covid-19治疗的随机化评估(恢复) trial, was set up in just ten days and already fifteen  patients have been recruited in Exeter. The trial is being run through a strong partnership between the University of Exeter and the Royal Devon & Exeter NHS Foundation Trust. Exeter is one of the 157 trial centres being coordinated nationally by researchers from the University of Oxford. There are currently no specific treatments for COVID-19. It is possible that some existing drugs usually used for other conditions may have some benefits – but they may not. As they are already approved for other uses, the trial is able to start more swiftly than for new drugs which would need rigorous safety testing first. The new trial will provide doctors and the health service with information they need to determine which treatments should be used.

The treatments initially included in the study have been recommended by an expert panel that advises the Chief Medical Officer in England. These are Lopinavir-Ritonavir, normally used to treat HIV, the steroid dexamethasone, which is used in a wide range of conditions to reduce inflammation, and hydroxychloroquine, which is mainly used as an anti-malarial drug and the commonly-used antibiotic azithromycin. The safety and side effects of the drugs are well known. The trial has seen research teams at the RD&E uniting to form a single workforce to ensure that patients have the best possible access to the ground-breaking COVID -9 studies being undertaken. The  aim is to promote the most positive outcomes for our patients following infection In the future, the RECOVERY trial may be expanded to assess the impact of other potential treatments as they become available.

Dr Ray Sheridan, Consultant at the Royal Devon & Exeter NHS Foundation Trust and Associate Clinical Professor at the University of Exeter, said: “This trial is an incredibly exciting development in the battle against COVID-19. In Exeter, the strong and long-standing relationship between the University and the RD&E health trust means our clinicians and scientists work incredibly well together. We don’t yet know if the drugs will work, but it’s heartening to be part of promising research on this international crisis. As a frontline clinician, I beg everyone to do their part to buy us time to develop this research. Stay home, wash your hands and when you must go out, observe social distancing measures.”

The trial will be open to adult inpatients at the Royal Devon & Exeter Hospital who have tested positive for COVID-19, and who have not been excluded for medical reasons. All patients will receive the usual standard of care. Patients joining the trial will be allocated at random by computer to receive one of the medicines being studied in addition to standard care, or standard full usual care n. This will enable researchers to see whether any of the possible new treatments are more or less effective than those currently used for patients with COVID-19.

亚光汉考克,状态健康和社会保健部长上周表示; “我们需要更多的专利,志愿者是这些试验的一部分,因为更大的审判,更好的数据和更快,我们可以推出治疗 - 如果,且仅当它被证明工作。但现在,为了保护自己和您的家人免受这种疾病的唯一方法就是留在家里。”

彼得horby,新发传染病和全球卫生医药,牛津大学,并为审判首席调查员的纳菲尔德部门的教授,他说:“'存在对患者covid-上最好的照顾可靠的证据,迫切需要19。通过精心设计的临床试验提供了可能的新的治疗方法是获取证据的最佳途径。入院治疗covid-19成人应提供机会参与本试验,并有助于为大家改善服务。所有患者将接受标准的全面医疗服务,无论哪个治疗组,他们被放置在“。

马丁蓝凌,在人口健康,牛津大学纳菲尔德部门医学和流行病学教授,副主任补充调查:“这次临床试验的流线型设计让同意患者大量轻松,不影响病人的安全或进行注册显著增加繁忙的医院及其工作人员的工作量。这样,我们可以迅速评估的潜在治疗药物covid-19的值,并提供给病人治病的最佳途径患有这种疾病的可靠信息“。

新的审判已经归类为一个紧迫的公共卫生研究性学习。它是一个圆形的项目之一,获得1050万£作为的一部分 £2000万快速反应的研究 由英国研究和创新投资,以及健康和社会保健通过国家卫生研究所的部门。 

英格兰,威尔士,苏格兰和北爱尔兰,与NHS的医疗主任的首席医疗官员曾写信给NHS信托要求他们全力支持新的审判。

 

克莱尔,56,其中第一患者恢复试验的埃克塞特臂成covid-19

在56岁的克莱尔·富勒没看见自己作为开发covid-19,尽管她弱及良好管理哮喘的风险特别高 - 但她在人群当中的第一批病人被招募,并在恢复试验的埃克塞特手臂治疗。

A healthy and active global manager for a veterinary company, Claire, from Tiverton in Devon, found herself in isolated treatment at the Royal Devon & Exeter Hospital (RD&E), on oxygen and facing conversations about her options for resuscitation.

克莱尔的考验开发干咳,当她的呼吸恶化如此严重,她被救护车送往医院后开始十天。 “我得到的地步,我几乎无法说话,我可以在整个房子几乎不能走路没有感觉淡淡的,说:”两个成年子女的母亲“太吓人了如何只是突然转向。”

Once in hospital, Claire’s COVID-19 test was returned positive, and she was offered the opportunity to sign up to the RECOVERY Trial – A national study led  by University of Oxford & run locally In Devon through a partnership between RD&E and University of Exeter. “I was more than happy to sign up,” said Claire. “I know about clinical trials through my work, and I felt it was the least I could do.”

克莱尔被分配了抗疟疾药物羟氯喹,并在她的肺部经历了刺痛,但她说,这是不可能建立这是否是治疗的结果。 “这是很难知道的任何变化是否与药物或病毒,”她说。 “花了一两天,我开始感觉好多了,但我可能永远不会知道这是否会发生呢。”

后在医院五天,克莱尔被允许回家。她说:“这是这样一个救济回家,但我仍然非常薄弱。我需要睡在淋浴之后。它可能需要长达四周的时间为我的肺完全恢复。

“The staff at the RD&E were absolutely fantastic, but they’re working under very difficult circumstances. They’re learning with each patient that comes in. They’re having to treat people in isolation conditions – so they wear masks and gloves and only stay long enough to do observations. That’s difficult for everyone involved.

“这种病毒可能袭击任何人,人们可以如此迅速恶化。请你只呆在家里做一切可能避免受凉它我会敦促人谁没有在医院结束了注册到恢复审理。越来越多的人谁这样做,就越发现有效治疗的机会。” 

日期:2020年4月9日

阅读更多大学新闻